{"id": "6402c910201352f04a00000c", "question": "Can losartan reduce brain atrophy in Alzheimer's disease?", "answer": "Question: Can losartan reduce brain atrophy in Alzheimer's disease? [34687634] : 1 [21624562] Yes, based on the evidence presented in the given material, losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease [17883890]", "pmids": ["34687634", "21624562", "17883890"], "pmid_titles": {"34687634": "(No title fetched)", "21624562": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine."}, "topk_used": ["34687634", "25871773", "23624169", "17883890", "15649697", "24754513", "23293020", "24633805", "7510447", "21624562"], "topk_titles": {"34687634": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23624169": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24633805": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "21624562": "(No title fetched)"}, "gold_ideal": ["No. 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease."], "gold_exact": ["no"]}
{"id": "64040edf201352f04a000011", "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "answer": "Question: Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease? [34146512] : 1 [24983746] Semagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted [15783264]", "pmids": ["34146512", "24983746", "15783264"], "pmid_titles": {"34146512": "(No title fetched)", "24983746": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease."}, "topk_used": ["34146512", "15783264", "29441009", "17182990", "18590355", "21971452", "19585948", "31738372", "11701639", "24983746"], "topk_titles": {"34146512": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "29441009": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "18590355": "(No title fetched)", "21971452": "(No title fetched)", "19585948": "Novel strategies for the prevention of dementia from Alzheimer's disease.", "31738372": "(No title fetched)", "11701639": "(No title fetched)", "24983746": "(No title fetched)"}, "gold_ideal": ["No. Pioglitazone did not delay the onset of mild cognitive impairment."], "gold_exact": ["no"]}
{"id": "61fa941ec9dfcb9c09000005", "question": "Should Intepirdine be used for Alzheimer's disease?", "answer": "Yes, Intepirdine is a possible option for Alzheimer's disease treatment [20375655] The evidence suggests that it may reduce the risk of developing Alzheimer's disease by elevating the risk for Alzheimer's disease (ApoE4) and increasing the levels of active and passive immunization strategies [24754513] However, further research is needed to confirm these findings [7510447]", "pmids": ["20375655", "24754513", "7510447"], "pmid_titles": {"20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA)."}, "topk_used": ["23334070", "24754513", "15649697", "10510805", "7510447", "23624169", "21624562", "18620875", "7579023", "20375655"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "23624169": "(No title fetched)", "21624562": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease."}, "gold_ideal": ["No. In a phase 3 clinical trial Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate Alzheimer's disease dementia patients."], "gold_exact": ["no"]}
{"id": "65ce88b71930410b13000001", "question": "Is Lecanemab approved for Alzheimer\u2019s Disease?", "answer": "Yes, Lecanemab is approved for Alzheimer's Disease [29441009] It is a humanized antiamyloid beta (A\u03b2) monoclonal antibody designed to treat AD [23334070] Lecanemab has shown promising results in clinical trials, including reducing cognitive decline and improving symptoms in patients with mild to moderate AD [20375655]", "pmids": ["29441009", "23334070", "20375655"], "pmid_titles": {"29441009": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease."}, "topk_used": ["23334070", "23624169", "29441009", "7579023", "20375655", "21996556", "20154508", "23334069", "21971452", "22393530"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21971452": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease."}, "gold_ideal": ["Yes. Lecanemab (Leqembi\u00ae) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment due to AD or mild AD dementia) with confirmed brain amyloid pathology."], "gold_exact": ["yes"]}
{"id": "66097092fdcbea915f000010", "question": "Amyloid-\u03b2 is associated with what diseases?", "answer": ": [12345678] Fibrous cross-\u03b2 aggregates (amyloids) and their transmissible forms (prions) cause diseases in mammals (including humans) and control heritable traits in yeast [29330303] [29330303] Fibrous cross-\u03b2 aggregates (amyloids) and their transmissible forms (prions) cause diseases in mammals (including humans) and control heritable traits in yeast [29441009] [20600609] Amyloid-beta peptides (Abeta) generated by proteolysis of the beta-amyloid precursor protein (APP) by beta- and gamma-secretases play an important role in the pathogenesis of Alzheimer's disease (AD) [20600609]", "pmids": ["29330303", "29441009", "20600609"], "pmid_titles": {"29330303": "(No title fetched)", "29441009": "(No title fetched)", "20600609": "(No title fetched)"}, "topk_used": ["22957288", "28649604", "22292124", "21487536", "29441009", "29330303", "22393530", "23316412", "20600609", "19228370"], "topk_titles": {"22957288": "Amyloid \u03b2-Related Angiitis Causing Coma Responsive to Immunosuppression.", "28649604": "(No title fetched)", "22292124": "Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.", "21487536": "(No title fetched)", "29441009": "(No title fetched)", "29330303": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "23316412": "(No title fetched)", "20600609": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics."}, "gold_ideal": ["Amyloid-\u03b2 is associated with Alzheimer's disease as well as many other neurodegenerative diseases like Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration and progressive supranuclear palsy These proteins have also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes", "Amyloid-\u03b2 (A\u03b2) is a peptide with 38-42 amino acids associated with the pathogenesis of Alzheimer's disease (AD). The most common form, A\u03b242, is the most neurotoxic.", "Amyloid-\u03b2 is associated with Alzheimer's Disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, amyloid-\u03b2-induced neurotoxicity and neurodegeneration, and other diseases.", "Amyloid-\u03b2 is associated with Alzheimer's disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, cerebral amyloid angiopathy, and AD.", "Amyloid-\u00ce\u00b2 (A\u00ce\u00b2) is associated with Alzheimer's disease (AD) and is known to promote chronic inflammatory responses in the brain. Additionally, A\u00ce\u00b2 accumulation is also found in age-related macular degeneration (AMD) and glaucoma.", "Amyloid-\u00ce\u00b2 is associated with Alzheimer's disease and age-related macular degeneration.", "Amyloid-\u03b2 is primarily associated with Alzheimer's disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and others.", "Amyloid-\u03b2 is associated with diseases such as Alzheimer's disease, Parkinson's disease, and type II diabetes, among others.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, and other amyloid diseases.", "Amyloid-\u03b2 is associated with Alzheimer's disease, multiple sclerosis, and other neurodegenerative diseases.", "\nAmyloid-\u03b2 is associated with Alzheimer's disease, Down syndrome, Parkinson's disease, and certain types of cancer. (Note: The role of amyloid-\u03b2 in Parkinson's disease and cancer is less clear.)", "Amyloid is associated with various diseases such as Alzheimer's disease, Parkinson's disease, type II diabetes, prion diseases, neurodevelopmental and neurodegenerative disorders, metabolic disorders, and certain types of cancer.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral scler", "Amyloid-\u03b2 is associated with amyotrophic lateral sclerosis, cardiovascular disease, multiple system atrophy, progressive supranuclear palsy, cancer, traumatic brain injury.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, age-related macular degeneration, and glaucoma.", "Amyloid-\u03b2 has been associated with neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, it has been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes", "Amyloid-\u03b2 is associated with amyotrophic lateral sclerosis, cardiovascular disease, Alzheimer's disease, Parkinson's disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.", "Amyloid-\u03b2 (A\u03b2) has been associated with several neurological diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, A\u03b2 has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with several neurodegenerative diseases including Alzheimer's disease (AD), Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP) and progressive supranuclear palsy.", "Amyloid-\u03b2 is associated with a range of diseases including Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-beta is associated with several diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy.", "Amyloid-\u03b2 has been implicated in several neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), and progressive supranuclear palsy. Additionally, research has shown that amyloid-\u03b2 may play a role in other neurological conditions such as Parkinson's disease and amyotrophic lateral sclerosis, as well as in non-neurological disorders like cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 (A\u03b2) is associated with several diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), and progressive supranuclear palsy (PSP). A\u03b2 deposition has also been linked to other neurological diseases, such as Parkinson's disease, amyotrophic lateral sclerosis, and retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, A\u03b2 has been implicated in cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.", "Amyloid-beta (A\u03b2) is associated with various neurodegenerative diseases, including Alzheimer's disease (AD), Lewy body disease (LBD), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, and age-related macular degeneration. A\u03b2 has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-beta is associated with a range of diseases, primarily neurodegenerative and retinal disorders. It is most notably linked to Alzheimer's disease but also connected to other conditions such as Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, and age-related macular degeneration.", "Amyloid-\u03b2 is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy. It has also been implicated in other conditions including Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy."], "gold_exact": [["Alzheimer's disease"], ["Lewy Body diseasse"], ["frontotemporal lobar degeneration"], ["Progressive Supranuclear palsy"], ["Cardiovascular disease"], ["Traumatic brain injury"], ["Diabetes"], ["Parkinson's disease"], ["age-related macular degeneration"], ["Glaucoma"], ["amyotrophic lateral sclerosis,"]]}
{"id": "65cfa6201930410b1300000e", "question": "Is Patisiran used for Transthyretin Cardiac Amyloidosis?", "answer": "Yes, Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality [28893208] The evidence suggests that this drug may be effective in reducing the accumulation of abnormal TTR and its pathogenic variants, leading to improved outcomes in patients with hATTR amyloidosis [28920433] However, further studies are needed to confirm these findings and assess the safety and efficacy of patisiran in treating hATTR amyloidosis [26243339]", "pmids": ["28893208", "28920433", "26243339"], "pmid_titles": {"28893208": "(No title fetched)", "28920433": "(No title fetched)", "26243339": "(No title fetched)"}, "topk_used": ["28893208", "19363993", "28922609", "28646538", "21624562", "22122056", "22815077", "28920433", "23054683", "26243339"], "topk_titles": {"28893208": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28922609": "(No title fetched)", "28646538": "(No title fetched)", "21624562": "(No title fetched)", "22122056": "(No title fetched)", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "28920433": "(No title fetched)", "23054683": "(No title fetched)", "26243339": "(No title fetched)"}, "gold_ideal": ["Yes. Patisiran can be used for Transthyretin Cardiac Amyloidosis"], "gold_exact": ["yes"]}
{"id": "660d7324fdcbea915f000040", "question": "How many people affected by Parkinson's Disease develop dementia?", "answer": "1 [8237620] According to the provided evidence, the diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG) [21624562] 2 [21996556]", "pmids": ["8237620", "21624562", "21996556"], "pmid_titles": {"8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "21624562": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly."}, "topk_used": ["23040035", "8237620", "2107926", "23624169", "21624562", "17244848", "21971452", "17182990", "17303592", "21996556"], "topk_titles": {"23040035": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "23624169": "(No title fetched)", "21624562": "(No title fetched)", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia.", "21971452": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "17303592": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly."}, "gold_ideal": ["Approximately a quarter of people affected by Parkinson's disease develop Parkinsonn's disease dementia.", "About 26.3% of individuals with Parkinson's Disease develop Parkinson's Disease Dementia (PDD), indicating a significant concern for those affected. However, this number may underestimate cognitive decline cases as not all are classified as PDD; other forms such as Lewy body dementia or Alzheimer's disease can also occur in these patients."], "gold_exact": [["25%"]]}
{"id": "6616a122fdcbea915f000058", "question": "Has statin use been associated with a higher risk of dementia?", "answer": "Yes, statin use has been associated with a higher risk of dementia [27300264] Studies have shown that higher levels of neuroticism (i.e., high stress levels) are associated with an increased risk of dementia, while lower levels of conscientiousness (i.e., low stress levels) are associated with a reduced risk [23567438] However, the exact mechanisms underlying this association remain unclear [16974109]", "pmids": ["27300264", "23567438", "16974109"], "pmid_titles": {"27300264": "(No title fetched)", "23567438": "(No title fetched)", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age."}, "topk_used": ["2107926", "22034058", "23567438", "27300264", "24633805", "21624562", "29441009", "21971452", "15783264", "16974109"], "topk_titles": {"2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "22034058": "(No title fetched)", "23567438": "(No title fetched)", "27300264": "(No title fetched)", "24633805": "(No title fetched)", "21624562": "(No title fetched)", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age."}, "gold_ideal": ["No, there is no strong evidence to suggest that statin use is associated with a higher risk of dementia. In fact, some studies have found that statin use may be linked to a reduced risk of dementia, particularly among patients with stroke. However, it's important to note that the relationship between statins and dementia risk is complex and may depend on various factors such as the type and duration of statin use, age, sex, and other health conditions. Further research is needed to fully understand the potential benefits and risks of statin use in relation to dementia.", "According to a systematic review and meta-analysis of observational studies, statin use is not associated with a higher risk of dementia or Alzheimer's disease. In fact, the study found that statin use was associated with a decreased risk of both dementia and Alzheimer's disease. This reduction in risk was similar for both lipophilic and hydrophilic statins, but high-potency statins showed a greater efficacy in reducing dementia risk compared to low-potency statins. These findings suggest that statin treatment does not carry a neurocognitive risk and may even have a potential favorable role in reducing the risk of dementia. However, randomized clinical trials are needed to further explore this potential neuroprotective effect."], "gold_exact": ["yes"]}
{"id": "663014c8187cba990d000020", "question": "What is Alzheimer's disease?", "answer": "Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease that corresponds to the most common cause of dementia worldwide [24434253] It is characterized by the accumulation of abnormal proteins called amyloid beta (A\u03b2) and tau, leading to neuronal death and loss of cognitive function [21715616] The exact causes of AD are still unknown, but genetic and environmental factors have been implicated [28884281]", "pmids": ["24434253", "21715616", "28884281"], "pmid_titles": {"24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "28884281": "(No title fetched)"}, "topk_used": ["29441009", "22009441", "27358062", "24434253", "24132372", "23861639", "20826658", "21715616", "24965601", "28884281"], "topk_titles": {"29441009": "(No title fetched)", "22009441": "(No title fetched)", "27358062": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "28884281": "(No title fetched)"}, "gold_ideal": ["Alzheimer's disease is a neurodegenerative disorder characterized by amyloid beta plaque and neurofibrillary tangles.", "Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain.", "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease.", "Alzheimer's disease is a neurodegenerative disorder. It's characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain, leading to memory loss and cognitive decline", "Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid in the brain, leading to memory loss and cognitive decline"], "gold_exact": []}
